Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China
Given that Hi-CHOP is not cost-effective at conventional WTP thresholds, a substantial price reduction or unnecessary procedures, and optimizing clinical workflows for Hi-CHOP would be necessary to make it an economically viable first-line option for DLBCL compared to R-CHOP.
Authors
- Hanxiao Zhu (ORCID: https://orcid.org/0000-0003-2843-5578)
- Tiantian Tao
- Yingtao Lin (ORCID: https://orcid.org/0000-0001-9168-0491)
- Jia Wang
- Xin Li (ORCID: https://orcid.org/0000-0003-3951-8061)
- Yuyang Sun (ORCID: https://orcid.org/0009-0004-0331-2533)
- Baolong Ding
- Lihong Gao
Institutions
- China Pharmaceutical University (CN)
- Soochow University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Fourth People's Hospital of Changzhou (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Risk Management and Healthcare Policy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.2147/rmhp.s553720
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China